News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation and Eli Lilly and Company (LLY) Release: Results of New Meta-Analysis Regarding CV Events in Linagliptin Phase 3 Trials Presented at American Diabetes Association



6/25/2013 11:05:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of comparators (placebo, glimepiride and voglibose). These findings were presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES